抗-HBc阳性滤泡性淋巴瘤结局更差且突变模式独特
研究纳入121例滤泡性淋巴瘤患者,检测HBV感染状态、临床特征及基因突变谱。抗-HBc阳性16例(13.2%),HBV DNA均不可测。抗-HBc阳性者诊断年龄更大、β2微球蛋白更高,10年无进展生存和总生存均显著更差,且多因素分析独立相关。基因突变谱显示抗-HBc阳性者ARID1A突变发生率更高且无EP300突变。
要点
- 抗-HBc阳性FL患者10年PFS和OS显著更差,多因素分析独立。
- 抗-HBc阳性FL患者ARID1A突变更常见且无EP300突变。
- 治疗期间未观察到HBV再激活或乙肝发作。
核心结论
- 已 resolved HBV感染的FL患者结局更差,独立于其他已知临床风险因素,且基因突变谱独特。
研究设计与样本
- 队列研究,纳入121例符合治疗标准并接受利妥昔单抗或含利妥昔单抗化疗的FL患者。
主要发现
- 抗-HBc阳性16例(13.2%),所有患者HBV DNA均不可测。
- 抗-HBc阳性者诊断年龄68.1岁 vs 57.2岁(P = .007),β2微球蛋白升高比例56.3% vs 28.9%(P = .04)。
- 抗-HBc阳性者10年PFS 12.9% vs 58.3%(P < .0001),10年OS 22.0% vs 86.2%(P < .0001),多因素分析仍显著。
- 抗-HBc阳性者ARID1A突变发生率更高且无EP300突变。
- 治疗和/或维持期间无HBV再激活或HBV肝炎发生。
临床怎么用
- 对FL患者应检测抗-HBc状态以进行风险分层。
- 抗-HBc阳性FL患者接受利妥昔单抗或含利妥昔单抗化疗时未观察到HBV再激活。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Epidemiological studies have demonstrated the association between hepatitis B virus (HBV) infection and B-cell non-Hodgkin lymphoma (NHL), mainly for diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). We studied a cohort of 121 patients with FL for HBV infection status, clinical features, and gene mutational profile. Anti-HBc was detectable in 16 patients (13.2%), although all had undetectable HBV DNA. Anti-HBcore+ (anti-HBc+) cases presented with older age at diagnosis than anti-HBc- cases (68.1 vs 57.2 years; P = .007) and higher β2-microglobulin (56.3% vs 28.9%; P = .04). All patients included in the study fulfilled criteria for treatment and received therapy with rituximab or rituximab-containing chemotherapy. There were no episodes of HBV reactivation or HBV hepatitis during treatment and/or maintenance. Remarkably, anti-HBc+ patients had significantly lower 10-year progression-free survival (PFS; 12.9% vs 58.3%; P < .0001) and overall survival (OS; 22.0% vs 86.2%; P < .0001), that remained at multivariate analysis. Gene mutational profiling of all cases showed that anti-HBc+ cases had higher incidence of ARID1A mutations and absence of EP300 mutations, 2 key epigenetic regulators in FL. Overall, our study shows that FL patients with resolved HBV infection have a worse outcome independently of other well-known clinical risk factors and a distinct gene mutational profile.
引用
- Fernández-Rodríguez C, Rodríguez-Sevilla JJ, Fernández-Ibarrondo L, et al. Worse outcome and distinct mutational pattern in follicular lymphoma with anti-HBc positivity. Blood Adv. 2022. PMID: 34649275. doi:10.1182/bloodadvances.2021005316
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。